Adding bortezomib to melphalan/prednisone beneficial for first-line myeloma treatment

摘要

Bortezomib plus melphalan and prednisone is a valuable first-line treatment for patients aged 65 years or older with multiple myeloma who cannot receive more aggressive treatment, a phase III study suggests (New England Journal of Medicine 2008;359:906).